Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
August 15 2019 - 2:14PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
|
FORM
12b-25
|
SEC
FILE NUMBER
000-52218
|
|
NOTIFICATION
OF LATE FILING
|
CUSIP
NUMBER
68235A101
|
(Check
one):
|
[ ]
Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ]
Form N-SAR [ ] Form N-CSR
|
For
Period Ended:
June 30, 2019
[ ]
Transition Report on Form 10-K
[ ]
Transition Report on Form 20-F
[ ]
Transition Report on Form 11-K
[ ]
Transition Report on Form 10-Q
[ ]
Transition Report on Form N-SAR
For
the Transition Period Ended: ______________
Nothing
in this form shall be construed to imply that the Commission
has verified any information contained herein.
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART
I — REGISTRANT INFORMATION
OncBioMune
Pharmaceuticals, Inc.
Full
Name of Registrant
Former
Name if Applicable
11441
Industriplex Blvd., Suite 190
Address
of Principal Executive Office
(Street and Number)
Baton
Rouge, LA 70809
City,
State and Zip Code
PART
II — RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if appropriate)
[X]
|
(a)
|
The
reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
|
|
|
[X]
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N-SAR, or N-CSR, or portion
thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly
report of transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on
or before the fifth calendar day following the prescribed date; and
|
|
|
|
[ ]
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART
III — NARRATIVE
State
below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report portion
thereof, could not be filed within the prescribed time period.
The
Registrant was unable to file our quarterly report on Form 10-Q within the prescribed time period b
ecause
it was not able to finalize its unaudited financial statements as of and for the fiscal quarter ended June 30, 2019 without
unreasonable effort and expense. That has now occurred, and the Company has now completed its procedures with respect to the Form
10-Q, which is being filed simultaneously herewith.
PART
IV— OTHER INFORMATION
(1)
|
Name
and telephone number of person to contact in regard to this notification
|
|
|
Andrew
Kucharchuk, CFO
|
|
225
|
|
227-2384
|
|
(Name)
|
|
(Area
Code)
|
|
(Telephone
Number)
|
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the
Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required
to file such report(s) been filed? If answer is no, identify report(s).
|
|
|
|
Yes [X]
No[ ]
|
|
|
(3)
|
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year
will be reflected by the earnings statements to be included in the subject report or portion thereof?
|
|
|
|
Yes [ ]
No [X]
|
|
|
|
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
|
OncBioMune
Pharmaceuticals, Inc.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
|
August
15, 2019
|
By:
|
/s/
Andrew Kucharchuk
|
|
|
Name:
|
Andrew
Kucharchuk
|
|
|
Title:
|
Chief
Financial Officer
|
INSTRUCTION:
The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and
title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of
the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority
to sign on behalf of the registrant shall be filed with the form.
ATTENTION
Intentional
misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001)